Enanta Pharmaceuticals, Inc.

280 articles with Enanta Pharmaceuticals, Inc.

• Enanta Pharmaceuticals to Participate in Two Investor Conferences in June 2021

  6/10/2021

  Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two virtual investor conferences being webcast in June

• Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress™ 2021 Sponsored by the European Association for the Study of the Liver

  6/3/2021

  Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress ™ 2021 Sponsored by the European Association for the Study of the Liver

• Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

  5/11/2021

  Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 at 1:20 p.m. ET.

• Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic Hepatitis B Virus Patients on Treatment with a Nucleoside Reverse Transcriptase Inhibitor

  5/6/2021

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced positive data from the first two dose cohorts of Part 2 of its Phase 1b study of EDP-514 in chronic hepatitis B virus (HBV) patients already being treated with a nucleoside reverse transcriptase inhibitor (NUC)

• Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2021

  4/29/2021

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2021, after the U.S. markets close on May 6, 2021.

• Enanta Pharmaceuticals to Present at Upcoming Investor Conferences - Mar 02, 2021

  3/2/2021

  Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at three upcoming virtual investor conferences

• Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference

  2/18/2021

  Enanta Pharmaceuticals to Present at SVB Leerink 10 th Annual Global Healthcare Conference

• Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET

  2/8/2021

  Broadened Hepatitis B Virus (HBV) Program with EDP-721, a New Oral HBV RNA Destabilizer, as a Potential Component of a Functional HBV Cure Regimen; Plan to Initiate Phase 1 Study Mid-2021 Initiated RSVTx, a Phase 2b Study of EDP-938 in Adult Hematopoietic Cell Transplant Recipients with Acute Respiratory Syncytial Virus (RSV) Infection Expanded RSV Program with a Discovery Initiative for Novel RSV L-Protein Inhibitors

• Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2020

  2/1/2021

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2020 after the U.S. markets close on February 8, 2021.

• Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

  1/26/2021

  Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team.

• Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2021 at the 39th Annual J.P. Morgan Healthcare Conference

  1/8/2021

  Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2021 at the 39 th Annual J.P. Morgan Healthcare Conference Announces New Oral HBV RNA Destabilizer, EDP-721, as an Additional Component Toward Functional HBV Cure; Expects to Initiate Phase 1 Study Mid-2021 Expands RSV Program with Introduction of Discovery Initiative for RSV L-Inhibitors

• Enanta Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/5/2021

  Enanta Pharmaceuticals, Inc. announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal presentation at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 8:20 a.m. Eastern Time.

• Enanta Pharmaceuticals Announces the Appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology

  1/5/2021

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology.

• 

  BioSpace Movers & Shakers, Dec. 11

  12/11/2020

  Biopharma and life science companies and organizations strengthen their leadership teams and boards with these Movers & Shakers.

• Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development

  12/8/2020

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development. Dr. Kieffer brings over 20 years of virologic research and pharmaceutical industry experience to Enanta, with proven expertise in drug

• Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

  11/23/2020

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2020.

• Enanta Pharmaceuticals to Present at Upcoming Investor Conferences

  11/18/2020

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: Evercore ISI 3 rd Annual Virtual HealthCONx Conference, Fireside Chat at 9:15 a.m. ET on December 1, 2020 Piper Sa

• Enanta Pharmaceuticals to Host Conference Call on November 23 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

  11/16/2020

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal fourth quarter and year ended September 30, 2020 after the U.S. markets close on November 23, 2020. Enanta management will host a conference call at 4:30 p.m. ET to discuss these

• Enanta Pharmaceuticals to Present at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference

  9/28/2020

  Enanta Pharmaceuticals, Inc. announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference on October 5, 2020 at 2:00 pm ET.

• Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis

  9/14/2020

  Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis -- Initial clinical data including safety, tolerability and pharmacokinetics expected in 2Q 2021 – WATERTOWN, Mass.--( BUSINESS WIRE )-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule d